Clinical trials: Graft Vs Host Disease
Solid Tumors
A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
Background \& Rationale: About 75% of US population living today will not die of cancer. There has been a recent report of a colony of cancer-resistant mice developed from a single male mouse that unexpectedly survived challenges…
- Trial name
- NCT00900497
- Testing
- White Blood Cells/Granulocytes
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Dipnarine Maharaj
Chronic Graft Versus Host Disease
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant.
- Trial name
- NCT07011810
- Testing
- Axatilimab, Biospecimen Collection, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancies
Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
This is a phase 2 open-label trial designed to evaluate the efficacy of tildrakizumab in improving graft-versus-host disease (GVHD)-free relapse-free survival after myeloablative allogeneic hematopoietic cell transplantation…
- Trial name
- NCT04112810
- Testing
- Tildrakizumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Medical College of Wisconsin
Nutrition Disorders, Gastrointestinal Disease
Review of Infant Oral Feeding and Skills
This study evaluates the infant's feeding skill level at discharge from the neonatal intensive care unit. The goal is to determine whether the ability to "full feed by volume" implies "full skill development" for infant oral…
- Conditions
- Nutrition Disorders, Gastrointestinal Disease, Deglutition Disorder, Feeding Difficulties
- Trial name
- RIOS (NCT06736743)
- Testing
- SMART Tool for Feeding Skill Assessment
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Wake Forest University Health Sciences
Cholelithiasis, Cholecystitis, Acute
Evaluation of Risk Factors Leading to Conversion From Laparoscopic Cholecystectomy to Open Surgery
This retrospective controlled study aims to evaluate risk factors that affect open conversion in laparoscopic cholecystectomy. Patient characteristics, medical history, biochemical and radiological studies of the patient will…
- Conditions
- Cholelithiasis, Cholecystitis, Acute, Cholecystitis, Chronic, Gallbladder Diseases
- Trial name
- NCT06244589
- Testing
- Laparoscopic cholecystectomy, Open-conversion cholecystectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 1,695 people
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Graft -Versus-host-disease
Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), and is classified as acute (aGVHD) or chronic (cGVHD).
- Trial name
- NCT02055625
- Testing
- Mesenchymal stromal cells
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Myelodysplastic Syndromes, Graft Vs Host Disease
CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome
This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat myelodysplastic syndrome…
- Conditions
- Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease
- Trial name
- NCT05617625
- Testing
- Busulfan, Melphalan, Fludarabine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Guenther Koehne
Intestinal GVHD, Steroid Refractory GVHD
Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013
The objective of the ORION study is to explore the changes of gut microbiota composition following MaaT013 administration and its impact on the immune system in GVHD patients.
- Trial name
- ORION (NCT05017688)
- Testing
- Blood and stool sample collection
- Where
- 9 sites in France
- Volunteers
- 40 people
- Sponsor
- MaaT Pharma
Graft vs Host Disease
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
In this study, a combination of two antibodies both conjugated to a cell-killing toxin (so-called immunotoxins) will be evaluated.
- Trial name
- NCT02027805
- Testing
- T-Guard
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Xenikos
Graft-vs-Host Disease, GVHD
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
This research study is trying to determine the safest dose of Brentuximab Vedotin that can be given to patients with chronic GVHD and see if chronic GVHD improves.
- Trial name
- NCT01940796
- Testing
- Brentuximab Vedotin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Chronic Graft Versus Host Disease
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease.
- Trial name
- NCT05996627
- Testing
- Belumosudil, Biospecimen Collection, Electronic Health Record Review
- Where
- 5 sites in United States
- Volunteers
- 82 people
- Sponsor
- Fred Hutchinson Cancer Center
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Chronic Graft-versus-host Disease
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
The purpose of this study is to see if bortezomib (Velcade) is effective in the treatment of refractory cGVHD.
- Trial name
- NCT01158105
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Baylor Research Institute
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
- Conditions
- Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
- Trial name
- NCT06016088
- Testing
- RSP-1502, Tobramycin inhalation solution
- Where
- 22 sites in United States, Australia
- Volunteers
- 71 people
- Sponsor
- Respirion Pharmaceuticals Pty Ltd
Chronic (> 2 Weeks) Critical Ischemia With Skin Defect in Lower Limbs
Viennese Registry on Patients With Chronic Critical Limb Ischemia
The rationale of this study is to establish a registry to detect and follow patients with CLI treated in Vienna. The Vienna CLI registry is meant to document the incidence, prevalence, and actual outcome of CLI patients in a real…
- Trial name
- NCT01233141
- Where
- Austria
- Volunteers
- 400 people
- Sponsor
- Medical University of Vienna
Pruritus Chronic, Kidney Diseases, Chronic
Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP
The goal of this clinical trial is to compare a new intravenous drug, Anruikefen, with a traditional oral medication, nalfurafine orally disintegrating tablets, in improving sleep quality in patients with chronic kidney…
- Conditions
- Pruritus Chronic, Kidney Diseases, Chronic, Renal Insufficiency, Chronic, Uremia; Chronic
- Trial name
- Anrikefon (NCT07380113)
- Testing
- Anrikefon, Nalfurafine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhujiang Hospital
Graft Versus Host Disease
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT
This is a phase I trial of LDE225 for the treatment of steroid-refractory chronic Graft Versus Host Disease (GVHD).
- Trial name
- NCT02086513
- Testing
- LDE225
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
The purpose of this study is to find out if a combination of drugs (these are called: cyclophosphamide, sirolimus, and mycophenolate mofetil) will protect participants better against graft vs.
- Conditions
- Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis
- Trial name
- NCT03018223
- Testing
- Fludarabine, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Graft Versus Host Disease
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
The participant is invited to take part in this study because they have chronic Graft versus Host Disease (cGVHD) that is not responding to standard treatment with steroids.
- Trial name
- NCT01954979
- Testing
- Abatacept
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
This phase I trial studies the side effects of using an investigational procedure (fecal microbiota transplantation [FMT]) in treating patients with severe acute gut graft-versus-host-disease.
- Conditions
- Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease, Severe Gastrointestinal Tract Acute Graft Versus Host Disease, Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease
- Trial name
- NCT04280471
- Testing
- Fecal Microbiota Transplantation Capsule
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.